Cargando…

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options

Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atheroscl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizvi, Ali A., Stoian, Anca Pantea, Janez, Andrej, Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615620/ https://www.ncbi.nlm.nih.gov/pubmed/34829807 http://dx.doi.org/10.3390/biomedicines9111579

Ejemplares similares

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
por: Vekic, Jelena, et al.
Publicado: (2022)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
por: Rizvi, Ali A., et al.
Publicado: (2021)

The Role of Fructose as a Cardiovascular Risk Factor: An Update
por: Busnatu, Stefan-Sebastian, et al.
Publicado: (2022)

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2023)

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study
por: Ikezaki, Hiroaki, et al.
Publicado: (2021)

Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
por: Vekic, Jelena, et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
por: Salmen, Teodor, et al.
Publicado: (2023)

Role of HDL function and LDL atherogenicity on cardiovascular risk: A comprehensive examination
por: Hernáez, Álvaro, et al.
Publicado: (2019)

Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies
por: Chen, Der-Yuan, et al.
Publicado: (2021)

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
por: Bica, Ioana-Cristina, et al.
Publicado: (2023)

Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol
por: Hirano, Tsutomu, et al.
Publicado: (2022)

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)

Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues
por: Rizvi, Ali A., et al.
Publicado: (2021)

Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
por: Sakamoto, Kentaro, et al.
Publicado: (2015)

Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene
por: López-Ruiz, Antonio, et al.
Publicado: (2009)

Increased Small Dense LDL and Decreased Paraoxonase Enzyme Activity Reveals Formation of an Atherogenic Risk in Streptozotocin-Induced Diabetic Guinea Pigs
por: Aslan, Mutay, et al.
Publicado: (2013)

Atherogenic Plasma Index or Non-High-Density Lipoproteins as Markers Best Reflecting Age-Related High Concentrations of Small Dense Low-Density Lipoproteins
por: Płaczkowska, Sylwia, et al.
Publicado: (2022)

Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus
por: Olusi, Samuel O, et al.
Publicado: (2011)

Editorial: Diet-microbe-host interactions in metabolic syndrome
por: Gradisteanu Pircalabioru, Gratiela, et al.
Publicado: (2023)

The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs
por: Silbernagel, Günther, et al.
Publicado: (2022)

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
por: Lawler, Patrick R., et al.
Publicado: (2017)

Elevation of small, dense low density lipoprotein cholesterol—a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos, North-Central Nigeria
por: Inaku, Kenneth O., et al.
Publicado: (2017)

Electronegative LDL from Rabbits Fed with Atherogenic Diet Is Highly Proinflammatory
por: Chang, Po-Yuan, et al.
Publicado: (2019)

Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity: A Possible Contributor to Increased Risk of Cardiovascular Disease in Diabetes
por: Rabbani, Naila, et al.
Publicado: (2011)

The Comparison of the Associations of Lipoprotein(a) and the Atherogenic Index of Plasma With Coronary Artery Calcification in Patients Without High LDL-C: A Comparative Analysis
por: Hong, Seung-Pyo, et al.
Publicado: (2023)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

Circulating MicroRNAs Implicate Multiple Atherogenic Abnormalities in the Long-Term Cardiovascular Sequelae of Preeclampsia
por: Dayan, Natalie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_clorhtkp50b2bjve4g260n1h7u